YolTech

CN
EN

CN
EN

Pioneering Gene Medicine
Delivering Lifelong Cures

Read More
Pioneering Gene Medicine
Delivering Lifelong Cures

Read More
Pioneering Gene Medicine
Delivering Lifelong Cures

Read More

Science

Genome Editing Platform

Novel Genome Editing Toolbox - YTDE & YolBE
AI-Powered Discovery Platform using Metagenomics Data

Read More
LNP Delivery Platform

Proprietary Lipid Library and In-house Manufacturing

Read More

Science

Genome Editing Platform

Novel Genome Editing Toolbox - YTDE & YolBE
AI-Powered Discovery Platform using Metagenomics Data

Read More
LNP Delivery Platform

Proprietary Lipid Library and In-house Manufacturing

Read More

Clinical Trial

YOLT-203 Primary Hyperoxaluria (PH1)

YOLT-203 is currently being evaluated in a global multicenter, randomized, double-blind, placebo-controlled study, the first pivotal trial of an in vivo gene-editing therapy for PH1. aiming to evaluate the safety and efficacy of YOLT-203 in reducing urinary oxalate levels and improving long-term renal outcomes.

Read More

NEWS

YOLTECH CAREERS

Join Our Team! Be a part of a team that is working hard to change the future of genetic medicines

Read More